Research Area: Inflammatory & autoimmune disease
Development Stage: Prediction
Goal: Preinfusion prediction of in vivo CRS in CAR-T patients, not possible with legacy technologies
to follow our data >[/ce_button]
Higher CAR-T product PSI was found to statistically associate with grade 3+ CRS (p = 0.0174). PSI was measured across CD4+ and CD8+ samples from 20 patients.
In particular, there were large increases in the production of effector and stimulatory cytokines in the 3+ CRS cohort. These results suggest that the combination of frequency and cytokine production levels of polyfunctional T cells in the product associate with toxicity to treatment with CAR T cells.1
to learn more >[/ce_button]